MannKind Corporation (NASDAQ: MNKD) announced it will present clinical and real-world data on Afrezza inhaled insulin at the American Diabetes Association's Scientific Sessions from June 5-8, 2026, in New Orleans.

The company will showcase nine poster presentations examining Afrezza's use in pediatric patients, automated insulin delivery systems, and gestational diabetes. Key presentations include a subgroup analysis from the INHALE-1 study comparing inhaled insulin to rapid-acting analogs in children and adolescents with diabetes, and treatment satisfaction data among youth who achieved target blood sugar levels.

The Food and Drug Administration set a target action date of May 29, 2026, for reviewing MannKind's supplemental application to expand Afrezza use to children and adolescents ages 4-17 with type 1 or type 2 diabetes. The FDA accepted the supplemental Biologics License Application for review in October 2025.

Afrezza received initial FDA approval for adult patients in June 2014. The inhaled insulin is delivered through MannKind's Technosphere technology and is administered at meal times using a portable inhaler.

The presentations will include data on dosing approaches, glycemic control outcomes, and patient-reported experiences. One study examines inhaled insulin use alongside automated insulin delivery systems, while another evaluates the treatment in gestational diabetes patients during controlled meal conditions.

MannKind will also present data on FUROSCIX, its subcutaneous furosemide injection for fluid overload in patients with diabetes.